Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Ola Landgren(University of Miami Health System), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Nikoletta Lendvai(Centro de Investigación del Cáncer), Neha Korde(United States Fish and Wildlife Service), Maryalice Stetler‐Stevenson(National Cancer Institute)
Cited by 114
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534